Completed PHASE3 INTERVENTIONAL NCT00286897

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Sponsor: Eisai Limited

Conditions Parkinson's Disease

Interventions E2007

Updated 7 times since 2017 Last updated: Nov 2, 2015 Started: Feb 28, 2006 Primary completion: Jun 30, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Parkinson's Disease, this trial is completed. The trial is conducted by Eisai Limited and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Limited

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aix-en-Provence, France , Arcugnano, Italy , Barcelona, Spain , Bayonne, France , Beelitz-Heilstätten, Germany , Belgrade, Serbia and Montenegro, Serbia , Berlin, Germany , Bialystok, Poland , Blackpool, United Kingdom , Bloemfontein, South Africa and 80 more locations